Navigation Links
Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease

om outside the U.S. A telephone replay will be available for a limited time following completion of the call by dialing (800) 642-1687 or (706) 645-9291, and entering reservation number 7199876. Participants can access the call over the Internet by visiting www.amarincorp.com where the call will be archived there for a limited period of time.

About the Huntington Study Group

The Huntington Study Group is a non-profit group of physicians and other healthcare providers from medical centers in the U.S., Canada, Europe and Australia, experienced in the care of Huntington's disease patients and dedicated to clinical research of Huntington's disease. The HSG central operating office and Clinical Trials Coordination Center are located at the University of Rochester.

About the European HD Network

The European HD Network is a non-profit group of physicians and other healthcare providers in Europe. The European HD network's aim is to provide a platform for professionals and people affected by HD and their relatives to facilitate working together throughout Europe. The European HD Network facilitates the conduct of natural history and interventional trials.

About Amarin

Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's core development pipeline includes Miraxion for CNS disorders, an oral formulation of apomorphine for treating patients with advanced Parkinson's disease, a nasal formulation of lorazepam for treating emergency seizures and our proprietary pre-clinical combinatorial lipid program.

Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.

For p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) ... received a written notice (the "Notice") executed by the ... of the Company, requesting that the Board of Directors ... for stockholder action by written consent relating to the ... director seat resulting from Ronald J. Kanterman,s departure (the ...
(Date:12/15/2009)... Ever wonder what something looks like up close and ... Personal Scanning Electron Microscope (PSEM), kicked off its "Send ... samples to be scanned by one of their PSEMs. ... of 100nm to 5mm and an imaging resolution of ... In addition, ASPEX will not only scan your sample, ...
(Date:12/15/2009)... the best plan at the right price ... end of the year, thousands of Nebraska Medicare beneficiaries ... This is when the state,s 268,000 Medicare beneficiaries ... up and pay for in 2010. ,, Prescription ... says Independent Retail Pharmacist Steve Osenbaugh, of Lincoln. ...
Breaking Medicine Technology:KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7ASPEX Kicks Off Free 'Send Us Your Sample' Microscopy Campaign 2Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans 2LenSar 3A New Laser Cure for Cataracts 6005 1LenSar 3A New Laser Cure for Cataracts 6005 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 14731 1BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 14731 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 14731 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 14731 4Houston and New York Cosmetic Dermatologist Paul M Friedman MD Launches Expansive New Website 60745 1Houston and New York Cosmetic Dermatologist Paul M Friedman MD Launches Expansive New Website 60745 2Houston and New York Cosmetic Dermatologist Paul M Friedman MD Launches Expansive New Website 60745 3
... Several new studies presented at the American Urological ... use of statins--commonly prescribed to lower cholesterol--may benefit men ... symptoms (LUTS). Several key research studies highlighting these benefits ... media on Monday, April 27 from 9 to ...
... Study for the Treatment of Advanced Prostate CancerPARSIPPANY, N.J., ... of a Phase IIIB clinical trial of degarelix for ... approved by the U.S. Food and Drug Administration (FDA) ... The announcement was made at the ...
Other Medicine Technology:New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5
(Date:12/16/2009)... 16 For ages, people from around the ... properties. Its soothing waters have a reputation that dates ... involvement with miracles. Now, with the introduction of two ... can enjoy the legendary benefits of Dead Sea salt ... lines contain all-natural Dead Sea salt and essential oils ...
(Date:12/16/2009)... More Americans have myopia now than in the ,70s, ... Myopia (nearsightedness) is more common in the United States ... National Eye Institute study shows. , Researchers compared National ... and white participants from 1971 to 1972 and from ... The participants were 12 to 54 years old. , ...
(Date:12/16/2009)... trial bottle sample with purchase of 90-count bottle. , ... ... announces a special free offer for a “Free 21-Count ... Formula , with the purchase of a 90-count bottle. Distributed ... in FDA approved facilities and blends the 6 most important medicinal ...
(Date:12/16/2009)... Request A Test, Ltd. is proud to announce being presented with ... Weatherhead 100 showcases the fastest growing companies in Northeast Ohio and ... to succeed. , ... (PRWEB) December ... being presented with the Weatherhead 100 Upstart Award on December 3, ...
(Date:12/16/2009)... perfect gift to give that special woman who has everything? ... Mary Schook introduces exceptional beauty products online while educating the public ... ... (PRWEB) December 16, 2009 -- The holidays are rapidly approaching ... woman who has everything? Why stem cells, of course!, , , ...
Breaking Medicine News(10 mins):Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2
... CUR, QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two ... the detection of prostate cancer,and GCC for the staging ... part of the growing trend to molecular diagnostics., ... the 34th,Annual International Clinical Ligand Assay Society Meeting, held ...
... Trainers For Peak ... Performance, LOS ANGELES, June 2 ... Cher, now the,Pussycat Dolls are working out with Bally. On the verge of ... for,their hot new single "When I Grow Up," the Pussycat Dolls are getting ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today that it has acquired,Physicians Home Health Care ... $12 million in cash. The transaction will be ... established by a group of physicians in 1984, ...
... of autoantibody-secreting cells, have emerged as promising new ... (RA). In particular, B cell depletion with ... RA patients resistant to standard disease-modifying antirheumatic drugs ... In large trials, about half of these ...
... 2 The International Rett Syndrome,Foundation announced today ... Chief Scientific Officer, beginning July 1. Dr. Horton ... of Rett,Clinics, a series of clinics throughout the ... addition, Dr. Horton will,assist the IRSF Board of ...
... There is still time to enter,the American Academy ... to boys and girls in two groups, grades 3-5 ... will be invited to attend,the 2008 AAP National Conference ... winners will receive $500 and up to $1,000 for ...
Other Medicine News:Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 2Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 3Health News:Pussycat Dolls Shape Up With Bally Total Fitness 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 3Health News:Study of anti-CD20 therapy effective B cell depletion 2Health News:The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer 2
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities, including eight ... for you to set to ... intuitive PowerEase® interface is faster ...
Medicine Products: